NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $77 | $426 |
| % Growth | – | -100% | -81.9% | – |
| Cost of Goods Sold | $0 | $1,203 | $18 | $30 |
| Gross Profit | $0 | -$1,203 | $59 | $396 |
| % Margin | – | – | 76.6% | 93% |
| R&D Expenses | $10,656 | $14,465 | $16,746 | $14,672 |
| G&A Expenses | $16,310 | $0 | $7,659 | $7,585 |
| SG&A Expenses | $16,310 | $14,078 | $7,659 | $7,585 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$95 | -$84 |
| Operating Expenses | $26,966 | $28,543 | $24,405 | $22,257 |
| Operating Income | -$26,966 | -$29,746 | -$24,346 | -$21,861 |
| % Margin | – | – | -31,618.2% | -5,131.7% |
| Other Income/Exp. Net | -$17,267 | -$53,201 | -$2,401 | -$1,399 |
| Pre-Tax Income | -$44,233 | -$82,947 | -$26,747 | -$23,260 |
| Tax Expense | $53 | $7 | $7 | $5 |
| Net Income | -$44,286 | -$82,954 | -$26,754 | -$23,265 |
| % Margin | – | – | -34,745.5% | -5,461.3% |
| EPS | -1.54 | -5.38 | -1.25 | -1.08 |
| % Growth | 71.4% | -330.4% | -15.7% | – |
| EPS Diluted | -1.54 | -5.38 | -1.25 | -1.08 |
| Weighted Avg Shares Out | 28,830 | 15,427 | 21,452 | 21,452 |
| Weighted Avg Shares Out Dil | 28,830 | 15,427 | 21,452 | 21,452 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,724 | $745 | $2,306 | $1,315 |
| Depreciation & Amortization | $0 | $1,203 | $1,210 | $1,244 |
| EBITDA | -$26,966 | -$80,999 | -$23,231 | -$20,701 |
| % Margin | – | – | -30,170.1% | -4,859.4% |